Sophia Gayle

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Combination Therapy

Dna Damage Response

Drug Administration

Magnetic Resonance

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Sophia Gayle, Timothy Paradis, Kelli Jones, Juan Vasquez, Vishwas M Paralkar
Antigen-independent tumor targeting by CBX-12 (alphalex ™ -exatecan) induces long-term antitumor immunity. Immunotherapy (2023)
Sophia Gayle, Timothy Paradis, Kelli Jones, Juan Vasquez, Vishwas M Paralkar
Antigen-independent tumor targeting by CBX-12 (alphalex ™ -exatecan) induces long-term antitumor immunity. Immunotherapy 14 (18) (2023)
Sophia Gayle, Timothy Paradis, Kelli Jones, Juan Vasquez, Vishwas M Paralkar
Antigen-independent tumor targeting by CBX-12 (alphalex ™ -exatecan) induces long-term antitumor immunity. Immunotherapy 14 (18) (2023)
Sophia Gayle, Timothy Paradis, Kelli Jones, Juan Vasquez, Vishwas M Paralkar
Antigen-independent tumor targeting by CBX-12 (alphalex ™ -exatecan) induces long-term antitumor immunity. Immunotherapy 14 (18) (2023)
Sophia Gayle, Timothy Paradis, Kelli Jones, Juan Vasquez, Vishwas M Paralkar
Antigen-independent tumor targeting by CBX-12 (alphalex ™ -exatecan) induces long-term antitumor immunity. Immunotherapy (2023)
Ukhyun Jo, Yasuhisa Murai, Keli K Agama, Yilun Sun, Liton Kumar Saha, Xi Yang, Yasuhiro Arakawa, Sophia Gayle, Kelli Jones, Vishwas Paralkar, Ranjini K Sundaram, Jinny Van Doorn, Juan C Vasquez, Ranjit S Bindra, Woo Suk Choi, Yves Pommier
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Molecular cancer therapeutics 21 (7) (2022)